G. Léothaud, X. Lesage, D. Lescut, D. Levasseur, A. M. Levêque et al., Plan de Cuques Saint Avertin

P. Silvestre, H. W. Spiess, F. Spilthooren, N. Stremsdoerfer, D. A. Tessier et al., Saint Gemmes sur Loire; Thevenet P., md, Saint Malo

D. Drossman, W. Whitehead, and M. Camilleri, Irritable bowel syndrome: A technical review for practice guideline development, Gastroenterology, vol.112, issue.6, pp.2120-2157, 1997.
DOI : 10.1053/gast.1997.v112.agast972120

R. Akehurst and E. Kaltenthaler, Treatment of irritable bowel syndrome: a review of randomised controlled trials, Gut, vol.48, issue.2, pp.272-82, 2001.
DOI : 10.1136/gut.48.2.272

J. Jailwala, T. Imperiale, and K. Kroenke, Pharmacologic Treatment of the Irritable Bowel Syndrome, Annals of Internal Medicine, vol.133, issue.2, pp.136-183, 2000.
DOI : 10.7326/0003-4819-133-2-200007180-00013

N. Talley, Pharmacologic therapy for the irritable bowel syndrome, The American Journal of Gastroenterology, vol.91, issue.1, pp.750-758, 2003.
DOI : 10.1016/S0140-6736(02)09712-X

B. Hahn, L. Kirchdoerfer, S. Fullerton, and E. Mayer, Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life, Alimentary Pharmacology and Therapeutics, vol.11, issue.3, pp.553-562, 1997.
DOI : 10.1046/j.1365-2036.1997.00160.x

S. Leong, V. Barghout, and H. Birnbaum, The Economic Consequences of Irritable Bowel Syndrome, Archives of Internal Medicine, vol.163, issue.8, pp.929-964, 2003.
DOI : 10.1001/archinte.163.8.929

M. Delvaux, Functional bowel disorders and irritable bowel syndrome in Europe, Alimentary Pharmacology and Therapeutics, vol.304, issue.s3, pp.75-84, 2003.
DOI : 10.1080/00365520152584770

E. Mayer and G. Gebhart, Basic and clinical aspects of visceral hyperalgesia, Gastroenterology, vol.107, issue.1, pp.271-93, 1994.
DOI : 10.1016/0016-5085(94)90086-8

J. Furness, W. Kunze, and N. Clerc, Nutrient tasting and signalling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine and immune responses, Am J Physiol (Gastrointest. Liver Physiol.), vol.277, pp.922-930, 1999.

J. Serrano and . Bedelix, Critique du pouvoir couvrant intestinal et mesure de la surface spécifique, Med Chir Dig, vol.22, pp.1-3, 1993.

J. Frexinos and F. Lamarque, Effet de la Montmorillonite beidellitique sur la concentration de l'hydrogène expiré, Am Gastroenterol Hépatol, vol.23, pp.235-241, 1987.

B. Meknini and P. Bernades, Etude comparative de l'effet de Bedelix sur la surproduction de gaz intestinaux induite par un repas riche en hydrates de carbone fermentescibles, Med Chir Dig, vol.23, pp.442-446, 1994.

D. Drossman, J. Richter, and N. Talley, The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment, 1994.

T. Perneger, A. Leplfge, J. Elter, and A. Rangemont, Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults, Journal of Clinical Epidemiology, vol.48, issue.8, pp.1051-60, 1995.
DOI : 10.1016/0895-4356(94)00227-H

E. Corazziari, P. Bytzer, and M. Delvaux, Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, vol.45, issue.5, pp.569-80, 2003.
DOI : 10.1046/j.1365-2796.2001.00891.x

M. Kamm, Entry criteria for drug trials of irritable bowel syndrome, The American Journal of Medicine, vol.107, issue.5, pp.51-59, 1999.
DOI : 10.1016/S0002-9343(99)00079-0

M. Camilleri, A. Northcutt, and S. Kong, Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial, The Lancet, vol.355, issue.9209, pp.1035-1075, 2000.
DOI : 10.1016/S0140-6736(00)02033-X

M. Camilleri and . Tegaserod, Tegaserod, Alimentary Pharmacology and Therapeutics, vol.106, issue.3, pp.277-89, 2001.
DOI : 10.1016/S0140-6736(00)02033-X

J. Novick, P. Miner, and E. Krause, A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, Alimentary Pharmacology and Therapeutics, vol.39, issue.2, pp.1877-88, 2002.
DOI : 10.1111/j.1572-0241.2000.02179.x

J. Kellow, O. Lee, and F. Chang, An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, vol.52, issue.5, pp.671-677, 2003.
DOI : 10.1136/gut.52.5.671

R. Jones, G. Holtmann, and L. Rodrigo, Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients, Alimentary Pharmacology and Therapeutics, vol.94, issue.11, pp.1419-1446, 1999.
DOI : 10.1016/0014-2999(87)90475-4